Reduce the Immunogenicity of therapeutic proteins. Maintain function and develop best-in-class biologics.
The ideal therapeutic is going to combine maximum efficacy with low recognition by the patient’s immune system. In the first stage we can use Immunitrack’s unique PrDx epitope prediction tool to identify those epitopes within the therapeutic that are likely to be recognized by the immune system. We can then screen the pool of immunogenic candidates and assess their true MHC binding properties using our NeoScreen™ Service.
The most likely immunogenic candidates undergo an “alanine scan.” This allows us to identify the amino acids that are responsible for binding within any peptide-MHC complex. Those amino acids that are responsible for anchoring the epitope can be replaced with alternatives, and the new epitope can be re-tested on the NeoScreen™ platform. In this way, we help our clients work their way towards a de-immunized therapeutic.